Why two huge anti-inflammatory heart trials failed
ZEUS suppressed CRP by the largest margin any anti-inflammatory heart trial has achieved, yet its hazard ratio for cardiovascular events landed at 0.99, a near-exact null result that shows lowering a blood marker doesn't guarantee lowering actual heart attack risk.
- What to do: Don't treat a single CRP reading as proof of high or low cardiovascular inflammation risk on its own; ask your doctor how it fits with your LDL, Lp(a) and overall risk profile instead of reacting to that number in isolation.
- Why it matters: Mendelian randomization studies show genetic variants that change CRP levels don't change cardiovascular disease risk, while variants that change LDL or Lp(a) do, so CRP is a correlated marker of inflammation, not a proven causal driver of heart disease.
- How to apply it: If you have a high Lp(a) on a blood test, know that current Lp(a)-lowering drugs still haven't proven a cardiovascular benefit in a completed phase 3 trial; aggressive LDL management remains the well-proven lever available today.
- Metrics: ZEUS enrolled over 6,300 patients with kidney disease and CRP above 2 mg/L; HORIZON enrolled about 8,300 patients with Lp(a) above 70 mg/dL and lowered Lp(a) by 70 to 80%, likely short of the roughly 100 mg/dL reduction modeling suggested was needed.
- Tools: Newer research is shifting from blood-based markers like CRP toward direct imaging of coronary artery inflammation, such as PET-MRI and CT-based fat attenuation index scans, to select patients more precisely for future anti-inflammatory drug trials.